{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:27Z","timestamp":1792783407550,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universidad de Cadiz","id":[{"id":"https:\/\/ror.org\/04mxxkb11","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Neoadjuvant chemotherapy (NACT) is reserved for tumours with a worse prognosis, introducing confounding by indication. Using sequentially adjusted Cox models to display confounding step by step, we assessed prognostic factors and the role of neoadjuvant therapy in a single-centre breast cancer cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective study of 461 women treated at a single Spanish hospital (2016\u20132018) and followed to March 2026 (median 7.3\u00a0years; 456 in survival analyses). Overall (OS) and disease-free survival (DFS) were estimated by the Kaplan\u2013Meier and Cox regression methods; proportional hazards were checked with Schoenfeld residuals and missing data handled by multiple imputation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Five-year OS and DFS were 89.7% and 86.0%. Independent prognostic factors were stage III\u2013IV (HR 3.9), triple-negative subtype (HR 2.4) and adjuvant radiotherapy (HR 0.32). The apparent adverse effect of neoadjuvant therapy (univariable HR 2.35) disappeared after stage adjustment (HR 1.6;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.17), with the same pattern for DFS; treated women differed chiefly in stage III\u2013IV (60% vs. 14%; standardised mean difference 1.09). Recovering missing histological grade from source reports abolished its apparent prognostic effect (HR 1.40, 0.82\u20132.39). The triple-negative excess risk was concentrated in the first three years (HR 4.8 vs 0.4; interaction\n                      <jats:italic>p<\/jats:italic>\n                      = 0.020).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>After adjustment for stage and tumour burden, the apparent adverse effect of neoadjuvant therapy is largely explained by confounding by indication rather than treatment although the small treated subgroup cannot exclude a modest residual effect. Sequentially adjusted Cox models display the confounding pathway explicitly, complementing propensity-score approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-026-04563-7","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T07:26:00Z","timestamp":1789889160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Confounding by indication in the evaluation of neoadjuvant chemotherapy: a sequential Cox analysis of an eight-year single-centre breast cancer cohort"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7297-6876","authenticated-orcid":false,"given":"Juan Jes\u00fas Fern\u00e1ndez","family":"Alba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel Vilar","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Valencia","family":"T\u00e9llez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"de Pablo Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves Maira","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Gonz\u00e1lez","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina S\u00e1nchez","family":"Porro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Fiol","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda Casaut","family":"Lora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia Garc\u00eda","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Gonz\u00e1lez","family":"Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,20]]},"reference":[{"key":"4563_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"4563_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cpet.2023.04.002","volume":"18","author":"M Roy","year":"2023","unstructured":"Roy M, Fowler AM, Ulaner GA, Mahajan A. Molecular classification of breast cancer. PET Clin. 2023;18:441\u201358.","journal-title":"PET Clin"},{"key":"4563_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5858\/arpa.2022-0070-RA","volume":"147","author":"X Zhang","year":"2023","unstructured":"Zhang X. Molecular classification of breast cancer: relevance and challenges. Arch Pathol Lab Med. 2023;147:46\u201351.","journal-title":"Arch Pathol Lab Med"},{"key":"4563_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159\u201382.","journal-title":"Ann Oncol"},{"key":"4563_CR5","doi-asserted-by":"publisher","first-page":"1209189","DOI":"10.3389\/fonc.2023.1178230","volume":"13","author":"YC Song","year":"2023","unstructured":"Song YC, Huang Z, Fang H, Tang Y, Jing H, Song YW, et al. Breast-conserving surgery versus mastectomy for treatment of breast cancer after neoadjuvant chemotherapy. Front Oncol. 2023;13:1209189.","journal-title":"Front Oncol"},{"key":"4563_CR6","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39:1485\u2013505.","journal-title":"J Clin Oncol"},{"key":"4563_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6930","volume":"13","author":"G Houvenaeghel","year":"2024","unstructured":"Houvenaeghel G, de Nonneville A, Cohen M, Sabiani L, Buttarelli M, Charaffe E, et al. Neoadjuvant chemotherapy for breast cancer: pathologic response rates but not tumor size has an independent prognostic impact on survival. Cancer Med. 2024;13:e6930.","journal-title":"Cancer Med"},{"key":"4563_CR8","doi-asserted-by":"publisher","first-page":"6007","DOI":"10.3390\/curroncol31100448","volume":"31","author":"F Ghasemi","year":"2024","unstructured":"Ghasemi F, Brackstone M. The impact of neoadjuvant versus adjuvant chemotherapy on survival outcomes in locally advanced breast cancer. Curr Oncol. 2024;31:6007\u201316.","journal-title":"Curr Oncol"},{"key":"4563_CR9","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00432-019-02919-x","volume":"145","author":"MC van Maaren","year":"2019","unstructured":"van Maaren MC, le Cessie S, Strobbe LJA, Groothuis-Oudshoorn CGM, Poortmans PMP, Siesling S. Different statistical techniques dealing with confounding in observational research: measuring the effect of breast-conserving therapy and mastectomy on survival. J Cancer Res Clin Oncol. 2019;145:1485\u201393.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4563_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46:399\u2013424.","journal-title":"Multivar Behav Res"},{"key":"4563_CR11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164\u201372.","journal-title":"Lancet"},{"key":"4563_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","volume":"81","author":"PM Grambsch","year":"1994","unstructured":"Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515\u201326.","journal-title":"Biometrika"},{"key":"4563_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2393","volume":"338","author":"JAC Sterne","year":"2009","unstructured":"Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393.","journal-title":"BMJ"},{"key":"4563_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167:268\u201374.","journal-title":"Ann Intern Med"},{"key":"4563_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023;381:e071674.","journal-title":"BMJ"},{"key":"4563_CR16","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s12885-024-12222-9","volume":"24","author":"Z Liu","year":"2024","unstructured":"Liu Z, Li J, Zhao F, Ren D, Li Z, Chen Y, et al. Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis. BMC Cancer. 2024;24:440.","journal-title":"BMC Cancer"},{"key":"4563_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102375","volume":"105","author":"AJ Kerr","year":"2022","unstructured":"Kerr AJ, Dodwell D, McGale P, Holt F, Duane F, Mannu G, et al. Adjuvant and neoadjuvant breast cancer treatments: a systematic review of their effects on mortality. Cancer Treat Rev. 2022;105:102375.","journal-title":"Cancer Treat Rev"},{"key":"4563_CR18","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.2340\/1651-226X.2025.43990","volume":"64","author":"M El-Naggar","year":"2025","unstructured":"El-Naggar M, Karakatsanis A, Valachis A. Real-world survival outcomes of neoadjuvant versus adjuvant chemotherapy in operable triple-negative breast cancer: a propensity score matched registry-based study. Acta Oncol. 2025;64:1334\u201341.","journal-title":"Acta Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04563-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04563-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04563-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T07:26:01Z","timestamp":1789889161000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04563-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":18,"alternative-id":["4563"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04563-7","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]},"assertion":[{"value":"8 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted within the breast-cancer research line approved by the Research Ethics Committee of C\u00e1diz (protocol code TFG-ASCM-2022; PEIBA code 0173-N-22; favourable opinion issued 24 February 2022), of which it represents a continuation. This study complied with the Declaration of Helsinki. Because of the retrospective design, the Ethics Committee waived the requirement for individual informed consent.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}